Mitosyl

Quick links to important sections

Mitosyl

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mitosyl

What is Mitosyl? Identity, Composition, and General Purpose

Property Description
Active Ingredients Zinc Oxide, Retinol (Vitamin A), Cod Liver Oil
Form Ointment (Topical Formulation)
Pharmacological Class Dermatological Protectant and Tissue Regenerator
Common Use Barrier Formation and Skin Conditioning
Origin Synthetic and Naturally Derived Components

What Type of Pharmaceutical is Mitosyl? (Identity and Classification)

Mitosyl is a multicomponent dermatological preparation, primarily classified as a dermatological protectant and tissue regenerator. This product is a stable ointment designed exclusively for topical administration. Its pharmacological action involves providing a protective and soothing effect through the formation of a mechanical barrier on the skin. The inclusion of Zinc Oxide is central to its role as an astringent and protective agent. The ointment form provides effective occlusive local protection against moisture and friction.


Composition: Active Ingredients and Origin of the Ointment

The functional composition of Mitosyl relies on the active ingredient Zinc Oxide complemented by Cod Liver Oil, which supplies Retinol (Vitamin A). Zinc Oxide acts as the primary inorganic, synthetic protectant. The Cod Liver Oil component is naturally derived, contributing Retinol for its role in epidermal regeneration. Combining barrier components like zinc oxide with vitamins is an approach used to enhance skin repair and protection. This multicomponent nature allows the preparation to perform both physical defense and tissue conditioning.


General Purpose: What is Mitosyl Used for at a Basic Level? (General Benefit)

The general purpose of the Mitosyl Ointment is to support and maintain the defense mechanisms of the skin barrier. The formulation achieves this by establishing effective barrier formation and localized epidermal regeneration stimulation. By combining the mild drying action of Zinc Oxide with the nourishing properties of the vitamin components, the ointment generally assists in conditioning and preserving the integrity of irritated or exposed skin areas. This foundation of tissue regenerator support and mechanical defense establishes its utility as a primary dermatological protectant used for non-specific, high-level skin protection.

What side effects are possible with Mitosyl?

Possible Side Effects and Safety Information

The regulatory safety profile of Mitosyl Ointment, a topical preparation containing Zinc Oxide and Retinol (Vitamin A)/Cod Liver Oil, is primarily focused on localized reactions consistent with its route of administration. Officially documented adverse effects are classified by health authorities mostly under Skin and Subcutaneous Tissue Disorders and Immune System Disorders.

Adverse Reaction Classifications

Category Regulatory Status
Application Site Reactions Not Known (Frequency cannot be estimated from available data)
Hypersensitivity Reactions Rare

Adverse events listed in official labeling include allergic contact dermatitis and symptoms of local irritation, such as redness, burning, or pruritus (itching) at the site of application. While systemic absorption is minimal, severe systemic hypersensitivity remains a high-level safety consideration for any medicinal product.

Safety Constraints and Restrictions

Use of Mitosyl Ointment is strictly contraindicated in individuals with a known history of hypersensitivity to any of the active components (Zinc Oxide, Cod Liver Oil, Retinol) or excipients. This is a fundamental regulatory limitation.

Additionally, official documents for this class of oil-based topical preparation include a specific caution regarding fire hazard. Regulatory bodies require notification that fabrics, such as clothing or bedding, which have come into contact with the ointment may be more easily ignitable and present a serious fire risk if exposed to an open flame or other ignition sources. The product is for external use only and contact with eyes or mucous membranes should be avoided.

Overdose and Emergency Response

The official regulatory profile for Mitosyl Ointment addresses two distinct exposure scenarios. Systemic overdose resulting from the intended topical use is considered unlikely by regulatory authorities. This classification is due to the minimal dermal absorption of the active ingredient, Zinc Oxide, through the skin, meaning systemic effects are not anticipated.

The primary regulatory focus is on accidental oral ingestion of the ointment, which can lead to documented manifestations of poisoning. Accidental swallowing can cause gastrointestinal symptoms including nausea, vomiting, stomach pain, and diarrhea. Less common symptoms include fever, chills, and irritation of the mouth and throat.

In such an event, official guidance strictly mandates that a Poison Control Center must be contacted immediately for instruction. Urgent medical help is required if the person develops severe signs such as trouble breathing or loss of consciousness. Management procedures in the emergency setting are typically symptomatic and supportive treatment, focusing on managing the clinical presentation and monitoring vital signs, as no specific antidote is available for these components.

Therapeutic Uses of Mitosyl

What Mitosyl Treats: Main Uses and Benefits


This medication is commonly used across conditions presenting with episodic or fluctuating manifestations, particularly in infants experiencing diaper rash (erythema gluteale). This medication is applied across therapeutic domains where additional symptomatic support is needed. The formulation is relevant in situations where skin integrity is affected and requires additional support for recovery and symptom management. It is relevant for easing symptoms associated with conditions such as diaper dermatitis, localized chafing, mild sunburn, and superficial abrasions or cuts.

The medication's use contributes to the formation of a protective barrier that may help reduce irritation from moisture and friction, and generally supports easing the overall burden of visible redness, inflammation, and accompanying soreness. It is relevant for managing symptom clusters that may become intense or disruptive, such as stinging, burning, and redness.

“This application supports the patient during difficult episodes by easing distress and promoting comfort, particularly where minor skin irritations are involved.”

The supportive benefit helps maintain comfort and assists with functional stability during recurrent episodes.


Quick Fact: Relief for Superficial Skin Irritation

Mitosyl is commonly used for managing symptoms that interfere with daily comfort, and is relevant for easing symptoms associated with minor and superficial skin damage arising from acute external factors.

Regulatory References

  1. Health Products Regulatory Authority (HPRA) Summary of Product Characteristics

Eligibility and Restrictions for Use

Mitosyl, an ointment typically containing Zinc Oxide and Cod Liver Oil, has a patient eligibility profile strictly governed by regulatory labeling, defining who is allowed to use the product and who is formally excluded.

Populations Excluded from Use

Classification Exclusion Criteria (Official Regulatory Labeling)
Contraindicated Populations Individuals with known hypersensitivity or allergy to Zinc Oxide, Cod Liver Oil, or any other excipient in the formulation.
Prohibited Skin Conditions Use is strictly prohibited on severely broken, superinfected, or weeping skin lesions.

Eligible and Conditional Populations

Classification Eligibility Status (Official Regulatory Labeling)
Age-Group Eligibility Established use in infants and babies for the management of diaper rash. It is also eligible for use by older children and adults for minor, non-infected skin irritations.
Pregnancy and Lactation Generally not contraindicated for topical use; however, regulatory documents commonly advise consulting a healthcare professional. If used while breastfeeding, application on the breasts must be avoided.
Eligibility Restrictions For all users, the ointment must be limited to cutaneous use and contact with eyes and mucous membranes must be avoided.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Mitosyl is defined by its formulation as a topical ointment containing Zinc Oxide and Retinol (Vitamin A), resulting in interactions that are strictly local rather than systemic.

Interaction Scope

Category Regulatory Statement
Interacting Product Categories Topical medicinal products containing Vitamin A or its derivatives (retinoids); Other topical products applied to the same skin area.
Mechanistic Basis Local Pharmacodynamic Additive Effect: The Retinol component contributes to an augmented local effect profile. Administration-Timing Interference: The Zinc Oxide barrier physically obstructs the action of co-administered topical products.

Official Interaction Statements and Constraints

Regulatory documentation mandates caution regarding two primary types of interaction. First, the co-administration of Mitosyl with other topical medicinal products containing Vitamin A or retinoid derivatives establishes a risk of an augmented local effect profile. This is classified as a local pharmacodynamic additive effect.

Second, the ointment's formation of an occlusive Zinc Oxide barrier layer requires the timing of administration to be separated from that of other topical medicinal products applied to the same skin area to ensure their intended local action is not physically inhibited. Due to minimal systemic absorption, the official regulatory profile documents no clinically significant systemic pharmacokinetic interactions, contraindications, or interactions with food, alcohol, or herbal products.

Mechanism of Action

How Mitosyl Works: Mechanism of Action

Immediate Physical Barrier and Fluid Control

This mechanism is defined by the non-pharmacological action of Zinc Oxide, which deposits on the skin to form a cohesive, inert mechanical barrier and exerts an astringent property by precipitating surface proteins. This physical blockade and fluid reduction prevent external chemical irritants and moisture from accessing the underlying tissue, resulting in the maintenance of barrier integrity and a physiological reduction in afferent signaling.

Nuclear Receptor-Mediated Cellular Regeneration

The active regenerative mechanism is driven by Retinol (Vitamin A), which, upon cellular uptake, modulates nuclear Retinoid Receptors ( RAR/ RXR). This receptor activation promotes the gene transcription necessary for keratinocyte proliferation and accelerated cell differentiation. This active signaling sequence promotes sustained re-epithelialization and structural organization of the epidermal layers.

Synergistic Anti-Inflammatory Modulation

The overall function is defined by dual-phase synergy: Zinc Oxide functions as an immediate passive physical structure while Retinol initiates active, delayed epithelial turnover. The mechanism also includes the Cod Liver Oil component, which supplies PUFAs that act as competitive substrates for COX/LOX enzymes, indirectly modulating the local inflammatory response by reducing the synthesis of pro-inflammatory mediators.

Dosage and Administration Information

This section details the administration guidelines for Mitosyl Ointment, which define the product's use through a specific route, frequency, and duration limits. Adherence to these guidelines establishes the standardized protocol for the product’s use.

Administration Scope

Feature Instruction
Route of administration Topical (cutaneous use).
Dosing schedule General Skin Irritation: Application several times per day. Infant Diaper Rash: Application 1 to 3 times per day.
Age-group rules A specific limited duration and frequency are designated for infants (nourrisson) receiving treatment for diaper rash.
Special procedural conditions The ointment must be applied directly and exclusively onto the irritated area of the skin.

Instruction Classifications

Classification Description
Administration method type Topical administration (Ointment).
Frequency pattern Divided use, multiple times per day regimen.
Use-context constraints The total duration of use is limited to 3 days for infant diaper rash or 5 days for general skin irritation.

Resulting Procedural Structure

The use of the product involves a fixed protocol:

  • The Mitosyl ointment is applied directly to the affected skin area.
  • The product is applied according to the labeled frequency (either 1 to 3 times daily or several times daily).
  • The procedure involves lightly massaging the ointment into the skin during application.
  • The total duration of the treatment course is designed not to exceed the specified limit (3 or 5 days).

This instructional framework establishes a topical, short-term, divided-use protocol for the ointment. This protocol defines the external administration route and the time limitation on the course of use, outlining the standardized approach to its administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mitosyl

The body of research was studied for the components of Mitosyl, specifically the active ingredients: Zinc Oxide as a barrier agent and Retinol (Vitamin A), supplied by Cod Liver Oil, with tissue conditioning properties. The available evidence contributes to understanding symptom patterns and is relevant in trials assessing short-term or episodic symptom patterns related to skin irritation.


Evidence Base for Diaper Dermatitis and Related Irritation

Research examining the use of topical barrier protectants, including those containing Zinc Oxide, has involved Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies were applied in research contexts involving fluctuating or unstable symptoms, such as the skin irritation associated with conditions involving periods of heightened symptoms. The populations evaluated were mainly infants and young children experiencing symptoms associated with diaper use.

Research examined outcomes related to physical discomfort, such as erythema severity (redness), and outcomes linked to inflammatory or irritative states. Studies monitored outcomes reflecting skin barrier function. Research describes patterns observed in the studies related to visible redness and outcomes related to skin barrier function during the short observation periods. Findings often indicate patterns related to both physical protection and properties associated with epidermal processes.


Studies Examining Minor Superficial Skin Damage and Abrasions

The evidence base for topical use in minor superficial wounds research examined its structure, largely derived from controlled experimental studies and mechanistic research applied in studies examining patient-reported experiences of discomfort. This research was relevant in research examining temporary physiological imbalance associated with minor skin disruptions.

Research explored outcomes related to the process of skin repair, such as epithelialization (skin renewal) for superficial injuries. Studies also monitored patient-reported outcomes describing perceived discomfort, such as associated burning or soreness. Research describes patterns observed in the studies related to how the skin evolved in the observed populations during the acute healing phase.


Research Gaps and Areas of Uncertainty

Research highlights what is known—and what is still uncertain—about this preparation. Data are still emerging for some applications, and certainty remains low in certain subgroups. Specifically, comparative evidence is lacking for head-to-head trials against the wide range of other topical products currently available.

Key limitations noted in the research include the variability in methodologies and the modest sample sizes in some of the more focused studies. There is insufficient long-term data describing skin function patterns following chronic use. Subgroup findings are uncertain, as most studies concentrated on the primary populations and conditions involving periods of heightened symptoms. The evidence contributes to the broader evidence landscape but does not provide individual predictions of outcome.

Key Studies & References

  1. Elucidating the role of zinc oxide in dermatitis of varied etiology across the age spectrum: a comprehensive review
  2. Comparative Study between Talcum and Zinc Oxide Cream for the Prevention of Irritant Contact Diaper Dermatitis in Infants
  3. Topical retinoids (vitamin a creams) - DermNet
  4. Skin care compositions containing zinc salts and retinoids (Patent WO2000032155A2)
  5. HPRA/EMA Regulatory Product Information: Summary of Product Characteristics (Used for context on data availability/regulatory framing)

Frequently Asked Questions (FAQ)

Common questions about Mitosyl (FAQ)


Q: Is Mitosyl available without a prescription?

A: Mitosyl is generally available without a prescription in many jurisdictions. The official regulatory documents confirm the conditions for its use as a non-prescription medicinal product.


Q: Is Mitosyl the same as other zinc oxide creams?

A: Mitosyl is classified as a multicomponent preparation, meaning it is not the same as simple zinc oxide creams. It combines the barrier protection of Zinc Oxide with the tissue-regenerating properties supplied by the Retinol (Vitamin A) component from Cod Liver Oil.


Q: What makes Mitosyl different from Sudocrem or Bepanthen?

A: The distinction lies in Mitosyl's specific active ingredients. Official documents state that Mitosyl contains Zinc Oxide for barrier formation and Retinol (Vitamin A) from Cod Liver Oil to act as a tissue regenerator. This combination defines its official regulatory profile, describing its dual mechanism of action.


Q: How quickly is Mitosyl expected to show an effect?

A: The mechanism of Mitosyl involves two phases. The barrier effect provided by Zinc Oxide begins immediately upon application, forming a physical shield. The regenerative and tissue-conditioning effects driven by the Retinol component, which support skin renewal, are part of a delayed, ongoing cellular process.


Q: Can Mitosyl cause a rash or irritation?

A: Official safety information lists potential adverse effects that are primarily related to localized reactions at the site of application. These can include symptoms of local irritation such as redness, burning, or itching (pruritus). Severe systemic hypersensitivity reactions have been reported, which are classified as rare in official documentation.


Q: Does Mitosyl interact with common skincare ingredients like salicylic acid?

  • A: Regulatory documents indicate that the Zinc Oxide component of the ointment forms a physical barrier layer. This barrier can physically obstruct the intended local action of other topical products, including common skincare or medicinal ingredients, if they are applied to the same skin area too closely in time.

Q: Is it normal for Mitosyl to feel greasy after application?

  • A: Mitosyl is classified as a stable, oil-based topical preparation and is formulated as an ointment. This physical property of the ointment formulation is what helps form a mechanical barrier, and it is consistent with a noticeable, often greasy, residue on the skin after application.

Q: Can Mitosyl be used on broken skin?

  • A: Official labeling strictly prohibits the use of Mitosyl on skin that is severely broken, superinfected, or weeping. Official labeling states the product is for application onto the irritated areas of the skin, within the specified use limits.

Q: Are there any preservatives in the Mitosyl formula?

A: While the core ingredients are Zinc Oxide and Cod Liver Oil/Retinol, official composition documents often list other components called excipients. These may vary by region and product line but often include components such as an antioxidant (e.g., BHT or Tocopherol) used to stabilize the ointment base.


Q: Can Mitosyl be used on the face?

A: Official instructions state that Mitosyl is for topical (cutaneous) use only. Official constraints mandate that contact with the eyes and mucous membranes must be avoided. No specific restrictions on application to facial skin are provided beyond this safety constraint.


Q: Is Mitosyl safe to use multiple times a day?

A: The official recommended frequency for Mitosyl depends strictly on the condition being addressed. For general skin irritation, the frequency is described as several times per day. For infant diaper rash, the frequency is more limited, set at 1 to 3 times per day.


Q: Are there different strengths of Mitosyl available?

A: The official regulatory documentation provided addresses the Mitosyl Ointment formulation with its specified concentration of active ingredients (Zinc Oxide and Cod Liver Oil/Retinol). Alternative strengths or different concentrations of the active ingredients are not detailed in the core documentation.


Q: What should I do if I accidentally swallow a small amount of Mitosyl?

A: Mitosyl is strictly for external use. If the product is accidentally swallowed, a poison control center should be contacted immediately. This is the standard procedure advised by regulatory bodies for any accidental ingestion of an external-use product.


Q: Is Mitosyl a barrier cream or a healing ointment?

A: Mitosyl is officially classified as both a dermatological protectant and a tissue regenerator. The protectant function comes from the Zinc Oxide barrier, and the tissue regenerator function is supported by the cell renewal properties of the Retinol (Vitamin A) component.


Q: Why do official documents mention Mitosyl being for 'minor' skin issues?

A: The official use is limited to minor skin issues due to the regulatory mandate limiting the maximum duration of use to a short, specified course (3 or 5 days). The existing research evidence primarily addresses short-term or episodic symptoms and the acute healing phase of minor skin disruptions.


Q: Are there situations where Mitosyl should be stopped immediately?

A: Use of Mitosyl is strictly contraindicated if there is a known hypersensitivity or allergy to any of its components. In the event that signs of a serious allergic reaction or severe, persistent local irritation develop, official safety guidance indicates that use must be stopped.


Q: How is the safety profile of Mitosyl generally described in regulatory reviews?

A: The safety profile is characterized by localized reactions due to the ointment’s minimal systemic absorption into the body. Officially documented adverse effects are primarily classified as mild local irritation and, rarely, hypersensitivity at the application site.


Q: Can Mitosyl be used on fungal skin infections?

A: Official labeling prohibits the use of Mitosyl on superinfected or weeping skin lesions. This constraint includes, but is not limited to, skin lesions that are superinfected.


Q: Does Mitosyl relieve pain or just protect the skin?

A: The mechanism of action describes Zinc Oxide contributing to a physiological reduction in afferent signaling (nerve input) from the irritated area. Research has also examined patient-reported outcomes related to perceived discomfort.


Q: What kind of research exists on Mitosyl's long-term use?

A: Regulatory reviews explicitly state that there is insufficient long-term data describing skin function patterns following chronic use of the product. Due to this research gap, official regulatory instructions limit the use of the product to a short, defined duration.


Q: Is Mitosyl available in a liquid or spray form?

A: The product addressed in the core regulatory documentation is the Mitosyl Ointment (Topical Formulation). Official materials do not reference or provide information on other dosage forms such as a liquid or spray.


Q: Does using Mitosyl affect the effectiveness of sunscreen?

A: The Zinc Oxide component forms a physical barrier layer that can obstruct the absorption or intended local action of other topical products. For this reason, official documents advise that the administration timing must be separated from that of other products, including sunscreen, applied to the same skin area.


Q: Do studies support Mitosyl's use for mild burns?

A: The research evidence base addresses the use of Mitosyl components for conditions related to minor superficial skin damage and abrasions. Use for mild burns is not explicitly studied in the core documentation but falls within the general scope of minor skin disruptions.


Q: What is the consistency of Mitosyl cream like?

A: Mitosyl is a stable, oil-based topical preparation classified as an ointment. This formulation is typically thick and designed to leave a protective, visible, and occlusive residue on the skin.


Q: Why might a doctor suggest an alternative to Mitosyl?

A: Official documentation outlines situations where Mitosyl should not be used, such as known hypersensitivity or the presence of superinfected or severely broken skin. Furthermore, regulatory reviews note a lack of comparative evidence against all other currently available topical products, which might prompt the suggestion of an alternative.


Q: Are there different concentrations of zinc oxide in various Mitosyl products?

A: The official regulatory information addresses the Mitosyl Ointment formulation with its specified concentration of Zinc Oxide and Cod Liver Oil/Retinol. Alternative concentrations of the active ingredients are not detailed in the core documentation.


Q: Can Mitosyl be used near the eyes or mouth?

A: Official safety constraints mandate that contact with the eyes and mucous membranes (including the inside of the mouth) must be avoided. This applies regardless of the proximity of the application area.

How should Mitosyl be stored and disposed of?

How to Store and Dispose of Mitosyl?

Storage Requirements

Official regulatory documentation defines specific constraints for storing Mitosyl Ointment to ensure product stability and safety:

  • Temperature: The product must be stored at a temperature that does not exceed 30 C (86 F), corresponding to controlled room temperature.
  • Stability: The ointment must not be used after the printed expiration date. Once the container is opened, the product should be used within a period of 12 months.
  • Child Safety: Mitosyl must be kept out of the sight and reach of children to prevent accidental exposure.

Disposal Instructions

Expired or unused portions of Mitosyl Ointment require proper disposal. The official instruction is to consult a pharmacist for guidance on how to safely discard the medication in accordance with local environmental and pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mitosyl found in:

A-Z Index: